Closing Surgical Gaps After Removing Large Flat Colon Polyps
Compares closing versus not closing the site after removing large flat bowel polyps in adults.
Plain-language title generated from the registry record
Registry title: Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps
Key facts
- Where
- Montreal, CanadaSee the site
Where in Canada
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Trial code
- NCT06807073
- Record updated
- 8 September 2026
- Original description
The goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal LSLs.Read full original descriptionShow less
Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps: A Randomized Controlled Trial
The goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal LSLs.
The hypothesis is that performing complete defect closure following EMR of large colorectal LSLs will result in lower rates of adverse events compared to cases where no defect closure is performed.
For participants with planned EMR, endoscopists will perform EMRs as per standard of care and:
* prophylactic defect closure will either not be performed (control group), or will be performed (experimental group); * then, patients will be called between 14 and 44 days after EMR to assess for possible adverse events, and electronic medical files will be verified for emergency room visits and healthcare received for an adverse event; * finally, patients will undergo follow-up colonoscopy 6 months and 18 months after randomization.
Inclusion: adult ≥18 years old; patients undergoing EMR for a large (≥20mm) colorectal LSL; patients providing written and informed consent for study participation.
Exclusion: inflammatory bowel disease; overt signs of deep submucosal invasive cancer (JNET 3); coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets <50 x 109/L); non-elective colonoscopy; poor general health (American Society of Anesthesiologists classification >III); pedunculated polyps (Paris class Ip, Isp); appendiceal orifice or terminal ileum invasion; pregnancy.